Status:
UNKNOWN
Effects of Renin-Angiotensin System Inhibitors in Peritoneal Dialysis Patients
Lead Sponsor:
Chiang Mai University
Conditions:
Peritoneal Dialysis
Eligibility:
All Genders
18+ years
Brief Summary
Among antihypertensive medications, RAS inhibitor classes, namely angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) have the most prospective data on mortality and ...
Eligibility Criteria
Inclusion
- Adult patients aged 18 years or over at the date of PD initiation
- Patients with ESKD who were undergoing PD either continuous ambulatory peritoneal dialysis or automated peritoneal dialysis between January 1, 2006, to December 31, 2017
- Received PD treatment more than 90 days in an outpatient nephrology clinic visit after the date of PD initiation
- Received of any outpatient prescriptions within 90 days after the date of PD initiation
Exclusion
- Previously been treated by maintenance hemodialysis (for more than 90 days) or initiated PD for acute kidney injury or after a failed kidney transplantation
- Died within 90 days after the date of PD initiation
- Received a combination of ACEIs and ARBs therapy
- Received ACEIs/ARBs within 180 days before PD initiation
- Had no information regarding ACEI/ARB dosage regimen during the follow-up period
- Inadequate follow-up clinical information on blood pressure monitoring
Key Trial Info
Start Date :
August 31 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2020
Estimated Enrollment :
1468 Patients enrolled
Trial Details
Trial ID
NCT04076930
Start Date
August 31 2019
End Date
March 1 2020
Last Update
November 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pharmacoepidemiology and Statistics Research Center, Faculty of Pharmacy, Chiang Mai University
Chiang Mai, Thailand, 50200